Could some AML patients ditch chemo pills after a year?

NCT ID NCT06557421

Recruiting now Disease control Sponsor: Institut Paoli-Calmettes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with acute myeloid leukemia (AML) who have responded well to a year of treatment with venetoclax and azacitidine can safely stop taking these drugs. Researchers will monitor 50 patients closely for signs of relapse and compare them to a similar group that continued treatment. The goal is to see if stopping therapy can maintain remission while reducing medication side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and azacitidine
What this could lead to: If successful, this could show that some AML patients can safely stop these drugs after a year of treatment, reducing side effects and medication burden.
What could go wrong: This is a small, early-phase study with only 50 participants. Stopping treatment may lead to relapse, and results may not apply to all AML patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Institut Paoli-Calmettes
RECRUITING

Marseille, 13273, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.